Top Tech Companies in Boston, MA (4,557)

Strong Revenue Growth: Sales are reported to have risen from about $39 billion (2023) to more than $43 billion (2025), with 2024–2025 gains attributed to institutional solutions, whole life, and annuities.

Profitability: Operating earnings are characterized as increasing from $2.8 billion in 2024 to nearly $3.9 billion in 2025, a company‑record level.

Investor Backing & Capital Strength: Capital levels are described as strong, with total adjusted capital at $34.4 billion in 2025 and high financial‑strength ratings maintained across major agencies.

Strong Revenue Growth: Revenue increased 19% in 2025 and accelerated in 2026 with 22% year-over-year growth in Q1 and 27% in Q2, while first-half 2026 revenue rose 25% year over year. Management raised full-year 2026 guidance to $94–96M, implying roughly 22–24% growth.

Customer Loyalty & Retention: Net Dollar Retention reached 117% in Q1 2026, indicating expanding spend from existing accounts after churn. Core genomics customers rose to 537 as of March 31, 2026, with record new customer additions in 2025.

Market Expansion: Geographic momentum is evident with Q1 2026 analysis volume up 28% in the U.S. and 31% in APAC, and EMEA revenue up 30%. Platform usage set records (e.g., 108,000 analyses in Q1 and 115,000 in Q2), with liquid biopsy volumes growing sharply.

Profitability: Operating income has risen materially alongside growth, with the latest quarter reporting meaningful GAAP and adjusted operating profits and expanding margins. This indicates the business is scaling while improving earnings quality.

Resilient & Sustainable Growth: Gross profit is expanding at a strong, accelerating pace, with both Cash App and Square contributing and management raising full‑year outlooks. Longer‑term disclosures also highlight multi‑year compounding in gross profit per user across ecosystems.

Cost & Operational Efficiency: A leaner organizational structure and disciplined spending have driven record adjusted operating margins and improved operating leverage. Efficiency gains appear to be a second engine alongside revenue drivers.

Investor Backing & Capital Strength: Recent financing includes a $50 million Series D anchored by Boehringer Ingelheim, following a Series C in 2025 and prior debt financing, indicating sustained access to strategic capital. The transfer of CT-155 commercialization responsibility alongside dedicated commercial funding further underscores capital support aligned with near-term growth plans.

Strategic Partnerships: Collaborations with major pharmaceutical companies such as Otsuka and Boehringer Ingelheim, alongside agreements with Indivior and Ultrahuman, reflect deepening partner engagement in development and commercialization. These alliances have produced FDA-authorized products and structured milestone and royalty pathways that reinforce external validation.

Product Line Growth: Multiple FDA authorizations (Rejoyn for MDD and CT-132 for migraine), the acquisition of AspyreRx, and an expanded pipeline spanning psychiatry, neurology, and cardiometabolic disease point to a broader, more mature portfolio. Positive Phase 3 results and commercialization preparations for CT-155 add momentum to this expansion.

Resilient & Sustainable Growth: Revenue has increased year over year to a new high, with all three major service lines posting gains despite a slower pace. Growth remains uneven by region, but the overall trajectory is upward over the last several fiscal years.

Future-Ready Strategy: Multi‑billion‑dollar investments in technology—especially nearly $1.5B in AI—along with acquisitions and scaling managed services indicate a deliberate pivot to future growth levers. Leadership attention to next‑generation audit and AI‑enabled capabilities underscores preparation for emerging demand.

Strong Market Position & Advantage: The organization is characterized as a leading global professional‑services network with broad scale across assurance, advisory, and tax and repeated external recognitions in select consulting categories. Reach across major multinational clients supports durable competitive positioning.

Strong Revenue Growth: ARR increased from $177M in 2024 to $218M in 2025, with reported ARR roughly doubling since 2021. Platform activity also expanded as GMV rose from $11.2B to about $14.6–$15B over the same period.

Profitability: The group was profitable throughout 2025, following earlier profitability in the core Platform business. This progression indicates improving operating leverage alongside continued expansion.

Diversified Revenue Streams: Newer products are contributing incremental revenue, with Mirakl Connect generating about $11.7M ARR in under a year and Mirakl Ads seeing a sharp rise in ad spend in 2025. Customer additions (45 global enterprises in 2025) and launches across marketplace and dropship broaden the commercial base.

Strong Revenue Growth: Recent results indicate FY2026 revenue rose 19% year over year to roughly $2.02B, with Q1 FY2027 revenue up 16% and ARR up 17%. This points to steady double‑digit expansion across both total and recurring revenue.

Customer Loyalty & Retention: Dollar-based net retention is reported around 110–111%, and ARR growth has tracked slightly ahead of revenue growth. These signals suggest existing customers are expanding usage alongside new logo additions.

Healthy Cash Flow: Company materials highlight strong free cash flow alongside growth, including substantial FY2026 free cash flow and robust margins in recent quarters. The business has also returned capital via notable share repurchases.

Strong Hiring & Retention: Hiring and headcount are expanding, with disclosures of 15,000+ global employees, thousands of new hires, and third‑party estimates indicating continued workforce growth. Available evidence also points to active internal mobility and a recent increase in active job postings.

Market Expansion: Geographic and client footprints are broadening, with 40+ offices and 1,700+ customers across 170+ countries alongside concrete investments in new and expanded locations such as Hyderabad and Kingston. These moves indicate scaling delivery capacity in major capability centers and new regions.

Innovation-Driven Growth: The offering mix is shifting toward AI, data, technology, and platforms, including proprietary solutions and product capabilities. Strategic moves such as Salesforce-focused acquisitions and collaborations, plus a Tulip solution partnership, extend capabilities beyond traditional consulting.

Strong Revenue Growth: Historical disclosures point to outsized growth (e.g., revenue increasing 5x in 2020 and more than tripling in 2021), and one dataset estimates revenue rose from $21M in 2023 to $31.9M in 2024. Together with an expanding customer base, this indicates continued commercial momentum.

Investor Backing & Capital Strength: Funding totals about $114.5M, including a $71M Series C backed by major firms, and the company attributes a new Boston office in 2023 to continued growth. This capital base and facilities expansion suggest ample resources to scale.

Market Expansion: The company reports serving 1,000+ companies and highlights new offices and international expansion, alongside recent senior hires in revenue and engineering to support scaling. These signals point to ongoing expansion in customers, footprint, and organizational capacity.

Profitability: Square gross profit increased year over year in 2025 and again in recent quarters, with gains driven by processing, software, and financial solutions like Square Loans. Filings indicate this momentum continued into 2026, with growth excluding hardware also improving.

Strong Market Position & Advantage: Square is described as a leader in small-business POS and commerce, serving millions of sellers and processing a very large volume of payments. Industry recognition and scale suggest durable competitive positioning in its core segments.

Market Expansion: International payment volume is growing faster than the U.S., and sectors such as food and beverage led recent gains. Seller acquisition accelerated late in 2025, indicating widening reach across geographies and customer segments.

Strong Revenue Growth: Recent results show revenue rising from $1.62B in FY2023 to $2.17B in FY2024, $2.67B in FY2025, and about $3.35B in FY2026, with Q4 FY2026 up 25% year over year. This trajectory, alongside mid‑20% ARR growth, indicates continued expansion rather than a stall.

Healthy Cash Flow: Cash generation is growing, with free cash flow rising to about $779M in FY2026 and a free‑cash‑flow margin near 23%. Non‑GAAP operating metrics, including an ~80% gross margin, underscore operating leverage.

Strong Market Position & Advantage: Industry evaluations list the company as a Leader in the 2026 Gartner Magic Quadrants for both SSE and SASE, with five consecutive years of SSE leadership. Expanding large‑enterprise adoption and thousands of customers support a durable position in its core zero trust/SSE markets.

Profitability: Net income rose to $6.79B in 2025 from $4.38B in 2024. The combined ratio improved materially (e.g., S&P-adjusted 89.7% in 2025 and high-80s in early 2026), indicating stronger underwriting performance.

Investor Backing & Capital Strength: Shareholders’ equity increased from about $22.2B in 2022 to $39.9B at year-end 2025 and exceeded $44B by mid-2026. External ratings actions (AM Best A affirmation in Sept 2025; S&P upgrade to A+ in July 2026) underscore improved capitalization.

Resilient & Sustainable Growth: S&P describes deliberate portfolio reshaping and expects 2–3% annual premium growth during 2026–2028. Management emphasizes disciplined, selective expansion following underwriting improvements, prioritizing durable returns over sheer volume.

Strong Revenue Growth: Revenue is reported to have expanded dramatically over a recent three-year period, earning recognition on a leading high-growth list. Feedback suggests this reflects substantial commercial traction rather than growth based solely on financing.

Strong Market Position & Advantage: Customer adoption spans 500+ MedTech companies, including deep penetration among the largest enterprises (e.g., 16 of the top 20). Feedback suggests this breadth and upmarket presence signal durable positioning within its niche.

Investor Backing & Capital Strength: Capital raised has surpassed $160M with a recent late-stage round and a valuation near the unicorn threshold. Feedback suggests this funding base supports continued product expansion, AI initiatives, and go-to-market scale.

Strong Revenue Growth: Evidence indicates revenue grew rapidly over the period recognized by Deloitte’s 2025 Technology Fast 500, with earlier multi‑year gains also cited. Consecutive Fast 500 placements suggest sustained top‑line momentum.

Market Expansion: The company reports 130+ customers, including 13 of the top 30 P&C carriers, and moved to a much larger Boston headquarters. Customer counts have increased markedly since earlier periods, indicating broader market reach.

Product Line Growth: Materials describe expansion beyond claims into policyholder service and the launch of Unite to connect carriers with service providers. These additions broaden use cases and deepen penetration within carriers.

Strong Revenue Growth: Reported results show revenue rising from $3.67B (2023) to $4.77B (2024) to $6.05B (2025), with early 2026 revenue and guidance pointing to further gains. Q1 2026 continued to grow year over year, alongside expanding sportsbook handle and average monthly payers.

Profitability: Reported results show Adjusted EBITDA improving from $181M (2024) to $620M (2025) and a shift to positive GAAP net income in 2025. Guidance indicates substantial Adjusted EBITDA for 2026.

Product Line Growth: Company disclosures describe rising iGaming revenue in 2025 and the launch of new offerings like Predictions and a consolidated “super app.” These additions broaden the business beyond traditional sportsbook and DFS.

Strong Revenue Growth: ARR is reported to have surpassed $200M by June 2026 after crossing $100M in early 2025, with five consecutive years of 100% year-over-year growth. This consistent doubling signals rapid scaling at substantial revenue levels.

Investor Backing & Capital Strength: Funding rounds include $75M in 2024 at a valuation above $1B and a $250M Series E in 2025 at a reported $2.2B, with total capital raised cited at $400M+. Such late-stage financing and rising valuations indicate robust access to growth capital.

Strong Market Position & Advantage: Adoption is described as reaching roughly 1 in 6 U.S. apartments, with deep penetration among large property managers and hundreds of operators. Expansion into healthcare and notable distribution relationships have broadened its commercial footprint.

Profitability: Bottom-line performance is strengthening, with consistent earnings beats, improved non-GAAP operating income, and durable free cash flow. Management is prioritizing margin expansion alongside operational efficiency.

Healthy Cash Flow: The business is generating solid free cash flow, with recent periods and guidance pointing to sustained cash generation. This supports stability even as revenue growth moderates.

Strong Market Position & Advantage: The company is repeatedly recognized as a leader in MDR, exposure management, and SIEM by major analyst programs. A large global customer base underscores established scale in its core markets.

Market Expansion: Platform scale has expanded materially from roughly $500B and 1.5M accounts in 2016 to $2T+ and 5M+ accounts, alongside wins with large institutions such as Vanguard, Corient, and Elevation Point. Feedback suggests adoption is broadening across major managed‑account platforms and enterprise wealth firms.

Innovation-Driven Growth: Active investment in new capabilities—including AI initiatives (Vestmark Pulse, a Boston Center for AI Research and Development), direct indexing, and UMA integrations with alternatives—signals an innovation-led roadmap. These launches indicate ongoing product expansion that supports personalization and tax-aware implementation at scale.

Strategic Partnerships: Relationships with firms such as BlackRock, Vanguard, Capital Group, T. Rowe Price, iCapital, and Dynasty are extending distribution and solution breadth. Recent selections to power custom model portfolios and enterprise platforms reinforce integration into key industry ecosystems.

Investor Backing & Capital Strength: Funding progressed from a 2022 seed to a 2023 Series A and a $27M Series B in 2025, led by established firms, indicating strong capital support. Independent listings also note roughly $44M+ raised to date.

Market Expansion: The customer base expanded from 1,000+ paying businesses in 2022 to 6,000+ across all 50 states by 2025–2026, signaling broader penetration. Reported booked business rose from $25M+ (2022) to $655M+ (2025) and $1.2B+ (2026), reflecting sharply higher platform activity.

Product Line Growth: Offerings evolved from AI-generated websites to a broader suite spanning marketing, bookings, payments, CRM/messaging, and an AI 'Sidekick' mobile app. This widening scope is accompanied by continued hiring across sales, product, engineering, and AI/ML to support scale.

Strong Market Position & Advantage: Ekotrope is positioned as the most widely used HERS rating software in the U.S., supporting roughly 1 in 4 new homes and serving 7,000+ builders with 400,000+ homes per year. Penetration spans hundreds of HERS rating companies and more than 40 utility new‑construction programs.

Investor Backing & Capital Strength: An $11M financing in October 2025, bringing tracked cumulative funding to about $15.9M, underscores continued capital support for expansion. Multiple independent profiles indicate the company has raised additional capital over time rather than a single one‑off event.

Product Line Growth: The company has expanded beyond its core RATER tool into Market Intelligence data products and solutions for utilities, builders, manufacturers, and lenders. Release history shows major version updates (e.g., Version 5.0 in 2025 with additional releases in 2026), indicating an active roadmap.